LatchBio reposted this
You either die a solution provider or you live long enough to see yourself become a drug discovery company. Or do you?... - We present the first comprehensive map of the Omics Solution Provider landscape - As biology advances exponentially, new multi-omic technologies to read, write, and edit cells (genome, proteome, metabolome, or epigenome) emerge every week, rapidly increasing the level of complexity. Techniques that would have made the cover of Nature Biotech ten years ago are now standard in experimental protocols. Skills that once required an entire PhD and postdoc to master are now routinely expected from a first-year research associate. How are we supposed to keep exploring the farthest boundaries of biological possibilities if even the most basic discoveries depend on such complex and rapidly changing multi-omic technologies? Enter biological solutions providers. They play a crucial role in transforming cutting-edge biology into accessible solutions by abstracting these complex but essential tools into services, kits, or instruments. Within Omics, solution providers usually focus on genomics, proteomics, multi-omics, single-cell, or spatial biology. Whether it's a $100 whole genome sequencing, a detailed mapping of the spatial epigenome at single-cell resolution, the sequencing of a million cells simultaneously, or high-throughput cloning of plasmids into bacteria—impossible feats a decade ago—can now be accomplished in just a few hours with the help of Ultima Genomics, AtlasXomics, Fluent Biosciences, or Seqwell, respectively. We wanted to break down the Omics Solution Provider space into a digestible format that anyone can understand. Through numerous conversations with researchers, scientists, academics, and customers, we sought to create a market map. Going into this, we understood that any categories we grouped them into would be reductionist. Some companies fit well into multiple categories, and others don’t fit well into any of them. We did our best to balance usability and accuracy. We also looked into the dataset (DM and I’ll share) and found some really interesting insights. DM me (or comment your email) and i'll share.
Tecan is gonna be alarmed to see they're a Service Provider, and not an Instrument company.
Joe Balsanek
3mo
Interesting read! Curious why you left out companies like Mission Bio, Vizgen, Nautilus, and Luminex?
Regarding proteomics, approaches based on mass spectrometry are by far the most widely used. Service providers such as Biognosys or Evotec should be mentioned. For Metabolomics, mass spec is the state-of-the-art technology, Metabolon being the leader in the field.
Chiara Reggio
3mo
I am a bit confused on why companies like 10x and Biorad are not in the instrument provider quadrant but in the kit provider for Single Cell? They have their own kits but they have to be run on their instruments. Same for LevitasBio.
Celine JAIMET
3mo
And BD is also missing with our Rhapsody 🥲
Carina Emery
3mo
Miltenyi Biotec should be up there too, though exactly where is hard to say since they have the MACSima for spatial biology and workflows for single-cell sample prep.
nice table but Fluigdim does not exist anymore (became Standard biotools), Miltenyi is missing, Akoya provides instruments, you are also missing Aliri Bio as Spatial biology provider, Shimadzu should also be there...
Amélie CASTRO
3mo
This table is great but not accurate. 10x is providing tools ( kits and instrument) for spatial biology and multi omics
Steve Pemberton
3mo
Alfredo Andere 🦖 great job and thanks for including Alpenglow Biosciences, but we should cross over spaces to include services, kit's, and instruments. We provide 3D spatial biology instrumentation, software for data processing, and services for 3D data analysis. Why 3D? because biology is inherently dimensional and only analyzing small 4 micron bits of tissue is misleading. To understand biology you must see it in all it's fullness.
Co-founder & CBO @ Vincere Biosciences | Conquering Age-Related Decline with AI-Driven Drug Discovery
3moCharts like that make me glad we avoided the provider rat race and committed early to drug discovery :)